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LETTER TO THE EDITOR
Successful Handling of Autoimmunity in X-linked Thrombocytopenia
(XLT) Using Mycophenolate Mofetil
To the Editor: A 12-year-old male, the only child of a non-
consanguineous Portuguese couple, was admitted in a tertiary
pediatric hospital in Lisbon because of severe auto-immune
hemolytic anemia (minimum value of hemoglobin 4.3 g/dl),
with strongly positive direct IgG Coombs test. He had a personal
history of mild eczema and a previous diagnosis of chronic im-
mune thrombocytopenic purpura (ITP), with persistently positive
titers for anti-platelet antibodies. The ITP had been resistant
to intravenous immunoglobulin G (IGIV) and was partially
controlled (platelet count over 50,000/ml) with corticosteroids
(prednisolone 2 mg/kg/day), despite two hospital admissions for
severe, uncontrolled thrombocytopenia.
During hospitalization the patient had severe hemolysis for
14 days despite the infusion of IVIG and the administration of
pulses of corticosteroids (30 mg/kg of methylprednisolone for
5 days), needing the transfusion of two units of packed red
cells. The platelet count was normal at admission but decreased
gradually to a minimum value of 25,000/ml, with normal mean
platelet volume (9 ﬂ). He was discharged from the Hospital after
27 days of hospitalization, on 1.5 mg/kg/day of prednisolone. As
outpatient he had a severe relapse with bicytopenia (hemoglobin
8 g/dl, platelets 20,000/ml) as prednisolone was weaned (at the
dose of 0.8 mg/kg/day), needing higher doses of steroids.
In the presence of a refractory Evans syndrome in an adolescent
with mild eczema, after excluding common causes of chronic ITP,
such as systemic lupus erythematosus, auto-immune lymphopro-
liferative syndrome (ALPS), common variable immunodeﬁciency
or HIV, direct sequencing of the WASP gene was performed,
revealing a missense mutation c.1378C>T (p.Pro460Ser) in
exon 11. This mutation had previously been described as causing
X-linked thrombocytopenia [1]. This patient had a score of 5 in
the WAS scoring system [2] (autoimmune hemolytic anemia and
idiopathic thrombocytopenic purpura), contradicting the classical
benignity attributed to XLT (scores 2 and 3) [3].
Due to the severity of the disease and the lack of control with
high and prolonged doses of corticosteroids, treatment with myco-
phenolate mofetil (MMF) 300 mg/m2 twice a day was proposed.
This was based on the excellent results previously reported of its
utilization in patients with immune dysregulation and Evans syn-
drome, namely in ALPS with more than 30 patients treated, 80%
of whom with prompt resolution of auto-immunity [4] and well
tolerated adverse events [5].
Mycophenolate mofetil (MMF) is a prodrug of mycophenolic
acid (MPA), an inhibitor of inosine monophosphate dehydrogenase.
MPA depletes guanosine nucleotides preferentially in T and B lym-
phocytes and inhibits their proliferation, thereby suppressing cell-
mediated immune responses and antibody formation. MPA also
inhibits the glycosylation and expression of adhesion molecules,
and the recruitment of lymphocytes and monocytes into sites of
inﬂammation and ﬁnally, it decreases the production of nitric oxide,
which contributes to its anti-inﬂammatory activity [6].
Within 4 weeks of starting MMF, we were able to stop the
corticosteroids, with complete resolution of the cytopenias. After
12 months of follow-up, the patient maintains a normal platelet
count and hemoglobin, with no relapses while receiving immuno-
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